Dr. Reeves: Well, I think that it comes probably from the lung. We have two experiments with tracheal fluid and it has the same kind of activity. I believe that it may contribute to the high vascular resistance in the fetus.
Dr. Murray: Jack, I'm concerned about the species variation that you mentioned in passing. The fetal circulation of all mammalian species has a high pulmonary vascular resistance and I think the first assumption would be that if there is a ubiquitous mechanism it would be similar among animals.
Dr. Reeves:
WeU, your concern is, also, our major concern. You would think that if we had touched upon a very important biologic mechanism that it would be active in many species. However, as we learn more about the Werent species we're impressed by how they accomplish the same job using different mechanisms. 
Platelet Survival Time in

P
ulmonary thromboembolism frequently complicates the course of patients with chronic airway obstruction. Platelets play an important role in arterial thrombosis,' and in at least some patients with venous thrombosis.2 This study examines the role of platelets in chronic obstructive airways disease ( C A 0 ) by measuring platelet survival time in patients with severe CAO.
Platelet survival time was measured by labelling the patient's platelets with 100-150 microcuries of 5lchromium and after reinfusion obtaining blood samples at two to three hours and daily for seven days. The platelet button is counted and by computer-assisted least-squares analysis a single exponent is fitted to the count-rate data to obtain the half-time. Normal platelet survival half-time is 3.67 f .04 days (mean f SEM; N=18) with a range of 3.3-4.2 days.3 Student's t test was used to statistically compare the means.
Platelet survival time was measured in 26 patients with severe CAO. Twenty of these patients had detailed pulrnonary function testing to confirm the diagnosis with average vital capacity (VC) 2.52 f .30 L (56 f 6.8 percent of predicted), average FEVI.~ = 0.77 .11L and average FEV/VC = 31 t 1.5 percent. The six remaining patients had clinical evidence for far advanced CAO.
Twenty-one patients were hypoxemic ( PA02 < 80 mm Hg) at the time of study and five had normal arterial oxygen tension. Thirteen patients were receiving chronic oxygen therapy at low flow rates4 and nine of these were hypoxemic when studied. Patients were taking a variety of drugs to maximize ventilation including xanthines, sympathornimetic mines and a few were taking prednisone. All were stable in respect to their ventilatory state. Informed consent was obtained.
Mean platelet survival time for these 26 patients with severe CAO was shortened (2.6 + ,13 days). Four patients had normal platelet survival (>3.3 days) and 22 were shortened.
Platelet survival did not correlate with patient age, pulmonary function studies or the presence or absence of cor pulmonale. Of the 21 patients with hypoxemia, 20 had shortened platelet survival and the mean, 2.4 + .14 days was significantly different from normal (p<0.001) and from the mean of five with severe CAO who had normal arterial oxygen tension (3.0 + .22 days) (Fig   1 ) .
Of the hypoxemic patients, nine were receiving lowflow oxygen and 12 were breathing room air. Mean platelet survival for the 12 non-oxygen-receiving hypoxemic patients was 2.3 + .17 days which was significantly shorter (p<0.01) than the mean of the oxy-HYPOXEMIC NORMOXEMK FIGURE 1. Mean platelet survival half-time ( fSEM) for hypoxemic patients with severe chronic obstructive airways disease compared to the mean of those with normal arterial oxygen tension ( normoxemic ) . gen-receiving hypoxemic patients (2.6 + .24 days). The one hypoxemic patient with normal platelet survival time was receiving oxygen.
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The platelet suppressant drug, sulhpyrazone, was administered to eight hypoxemic patients with shortened platelet survival. The drug was given for three months at a dosage of 800 mg po per day and platelet survival remeasured. Three patients received oxygen during the period of sulhpyrazone therapy. Sulfinpyrazone prolonged platelet survival time in each of these eight patients and normalized platelet survival in one patient. Mean pre-treatment survival was 2.2 + .12 days and was prolonged to 2.9 + .I7 days (p<0.001) by sulfinpyrazone (Fig 2) . Arterial blood oxygen tension was not altered during sullbpyrazone therapy.
Results suggest that patients with severe CAO have shortened platelet survival time and that shortened platelet survival is associated with hypoxemia. As platelet survival time correlates with a history of thromboembolism in patients with substitute cardiac valves3*6 and rheumatic heart disease,e platelets may play a critical role in the thrombosis of hypoxemic patients with CAO.
Prolongation of shortened platelet survival time by sulhpyrazone also supports a role for platelets in thrombosis in CAO. The data comparing hypoxemic patients who are receiving oxygen with hypoxemic patients who are not receiving oxygen suggest that oxygen also alters shortened platelet survival. We have not studied platelet survival before and after initiating oxygen therapy and this should be done. Sulfinpyrazone prolonged platelet survival in 3 hypoxemic patients who were receiving oxygen.
Shortened platelet survival has also been observed in hypoxemic patients with primary pulmonary hypertension and the Eisenmenger syndrome and sullbpyrazone prolongs shortened platelet survival in these ~a t i e n t s .~ The data suggest that sulhpyrazone or other platelet suppressant agents might be of benefit in reducing thrombosis in hypoxemic patients with severe CAO. 
